首页> Recent patents on drug delivery & formulation> The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease

The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease

导出原文传递

翻译打印收藏纠错

第一作者： Kadiyala,I.

作者： Kadiyala,I. ^[1] ; Jacobs,D.

作者单位： Vertex Pharmaceuticals Incorporated, 130 Waverly St., Cambridge, MA 02139-4242, United States ^[1]

关键词 5-ASA Apriso Asacol Asacol HD Crohn's disease and ulcerative colitis Inflammatory bowel disease Lialda Mesalamine Oral delivery Pentasa

发布时间 2014-09-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Recent patents on drug delivery & formulation

2014年8卷1期

3-11页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Recent patents on drug delivery & formulation

2014年8卷1期

3-11页

检索历史清除

The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease

Recent patents on drug delivery & formulation

相似文献

同项目论文

Recent patents on drug delivery & formulation

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease

Recent patents on drug delivery & formulation

相似文献

同项目论文

Recent patents on drug delivery & formulation

相关期刊

检索历史清除